IP Library › Granted Patent US 12,649,907
Granted Patent B2
US 12,649,907 · App. 17/432,156 · Granted Jun 9, 2026

Alternate detergents for viral inactivation

Inventors: Gabriella Perell (Thousand Oaks, CA); Rosa Daneshvar (Thousand Oaks, CA); Martina Kopp (Thousand Oaks, CA)
Assignees: AMGEN INC.; Avantor Performance Materials, LLC
C12N7/00C07K1/16C07K1/34C12P21/00C12N2740/13063
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,649,907
App. No.
17/432,156
Granted
Jun 9, 2026
Kind
B2
Abstract

Detergents for use to inactivate enveloped viruses, including detergents that are considered eco-friendly that can be used in biomanufacturing operations.

Claims (37)

1 . A method for inactivating envelope virus in a fluid known or suspected to contain at least one enveloped virus, comprising

obtaining a fluid known or suspected to contain at least one enveloped virus;

exposing the fluid to a detergent having a CAS registry number of CAS 3055-99-0, CAS 9043-30-5, CAS 181135-58-0, CAS 181135-57-9, CAS 250692-65-0, CAS 228579-27-9, CAS 349477-49-2, CAS 70504-28-8, CAS 59080-45-4, CAS 69984-73-2, CAS 148616-91-5, CAS 148565-55-3, CAS 82494-09-5, CAS 253678-67-0, CAS 106402-05-5, or CAS 93911-12-7;

at a detergent concentration that is 2.5× to 10× of its Critical Micelle Concentration (CMC) and time sufficient to cause viral inactivation.

2 . The method according to claim 1 wherein the fluid is exposed to the detergent for at least 30 seconds to at least 60 minutes or longer.

3 . The method according to claim 2 wherein the fluid is exposed to the detergent for at least 10 minutes.

4 . The method according to claim 1 , wherein the detergent concentration is at least 5× of its CMC.

5 . The method according to claim 1 , wherein exposure of the fluid to the detergent occurs at a temperature of at least 5° C. to 22° C.

6 . The method according to claim 5 , wherein exposure of the fluid to the detergent occurs at a temperature of at least 15° C.

7 . The method according to claim 1 , wherein the detergent concentration is 5× of its CMC and the time is at least 10 minutes.

8 . The method according to claim 1 , wherein the fluid comprises a recombinant protein of interest.

9 . The method according to claim 1 , wherein the fluid is harvested host cell culture fluid.

10 . The method according to claim 1 , wherein the fluid is from an effluent stream, eluate, pool, storage or hold from a unit operation comprising a harvest step, a filtration step or a chromatography step.

11 . The method according to claim 10 , wherein the fluid is

(i) eluate collected from depth filtration, microfiltration, affinity chromatography, ion exchange chromatography, multimodal chromatography, hydrophobic interaction chromatography or hydroxyapatite chromatography; or

(ii) a pool containing harvested cell culture fluid, eluate from depth filtration, eluate from microfiltration, eluate from affinity chromatography, eluate from ion exchange chromatography, eluate from multimodal chromatography, eluate from hydrophobic interaction chromatography, or eluate from hydroxyapatite chromatography.

12 . The method according to claim 11 , wherein the affinity chromatography is Protein A, Protein G, Protein A/G, or Protein L chromatography.

13 . A method for inactivating enveloped viruses during purification of a recombinant protein of interest comprising

obtaining a fluid comprising the recombinant protein of interest which is known or suspected to contain at least one virus;

subjecting the fluid to at least one detergent, wherein the detergent has a CAS registry number of CAS 3055-99-0, CAS 9043-30-5, CAS 181135-58-0, CAS 181135-57-9, CAS 250692-65-0, CAS 228579-27-9, CAS 349477-49-2, CAS 70504-28-8, CAS 59080-45-4, CAS 69984-73-2, CAS 148616-91-5, CAS 148565-55-3, CAS 82494-09-5, CAS 253678-67-0, CAS 106402-05-5, or CAS 93911 12-7 at a detergent concentration that is 5× of its Critical Micelle Concentration (CMC) and for at least 10 minutes to cause inactivation of enveloped viruses in the fluid; and

subjecting the viral inactivated fluid to at least one unit operation which includes at least a filtration step or a chromatography step.

14 . The method according to claim 13 , wherein the chromatography is selected from affinity chromatography, Protein A chromatography, ion exchange chromatography, anion exchange chromatography, cation exchange chromatography; hydrophobic interaction chromatography; mixed modal or multimodal chromatography, or hydroxyapatite chromatography.

15 . The method according to claim 13 , wherein:

(i) the fluid is harvested host cell culture fluid and the unit operation includes depth filtration;

(ii) the fluid is harvested host cell culture fluid and the unit operation includes microfiltration;

(iii) the fluid is harvested host cell culture fluid and the unit operation includes Protein A affinity chromatography; or

(iv) the fluid is Protein A eluant and the unit operation includes depth filtration.

16 . The method according to claim 13 , wherein the unit operation includes depth filtration or microfiltration.

17 . The method of claim 1 , wherein the detergent has a CAS registry number of CAS 3055-99-0 or CAS 9043-30-5.

18 . The method of claim 13 , wherein the detergent has a CAS registry number of CAS 3055-99-0 or CAS 9043-30-5.

19 . The method of claim 17 , wherein the detergent has a CAS registry number of CAS 3055-99-0.

20 . The method of claim 17 , wherein the detergent has a CAS registry number of CAS 9043-30-5.

21 . The method of claim 18 , wherein the detergent has a CAS registry number of CAS 3055-99-0.

22 . The method of claim 18 , wherein the detergent has a CAS registry number of CAS 9043-30-5.

23 . A method for inactivating envelope virus in a fluid known or suspected to contain at least one enveloped virus, comprising

obtaining a fluid known or suspected to contain at least one enveloped virus;

exposing the fluid to a detergent which is TDA-9, at a detergent concentration that is 2.5X to 10X of its Critical Micelle Concentration (CMC) and time sufficient to cause viral inactivation.

Assignments (5)
PATENT SECURITY AGREEMENT Recorded Jul 14, 2026
From: AVANTOR FLUID HANDLING, LLC; AVANTOR PERFORMANCE MATERIALS, LLC; NUSIL TECHNOLOGY LLC
To: GOLDMAN SACHS BANK USA
Reel/Frame 075975/0182 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 22, 2025
From: VAN BUSKIRK, RUSSELL
To: AMGEN INC.
Reel/Frame 072645/0032 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 29, 2025
From: AMGEN INC.
To: AVANTOR PERFORMANCE MATERIALS, LLC; AMGEN INC.
Reel/Frame 071862/0311 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 19, 2024
From: PERELL, GABRIELLA; DANESHVAR, ROSA; KOPP, MARTINA
To: AMGEN INC.
Reel/Frame 068637/0451 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 19, 2024
From: DEORKAR, NANDU; OH, JUNGMIN
To: AVANTOR PERFORMANCE MATERIALS, LLC
Reel/Frame 068637/0458 →
Continuity (2)
Provisional Application 62820330 · Mar 19, 2019
Related Publication 20220106573A1 · Apr 7, 2022
References Cited (41)
US 6319494B1 · Capon et al. · 2001 [cited by applicant]
US 7067298B2 · Latham et al. · 2006 [cited by applicant]
US 7741465B1 · Eshhar et al. · 2010 [cited by applicant]
US 10611795B2 · Fisher et al. · 2020 [cited by applicant]
US 20120015862A1 · Travis et al. · 2012 [cited by applicant]
US 20150306223A1 · Conley et al. · 2015 [cited by applicant]
US 20160333046A1 · Fisher et al. · 2016 [cited by applicant]
US 20200032163A1 · Bouchez et al. · 2020 [cited by applicant]
CA 2228031A1 · 1997 [cited by applicant]
WO 9704815A1 · 1997 [cited by applicant]
WO 0228422A2 · 2002 [cited by applicant]
WO 2004090114A2 · 2004 [cited by applicant]
WO 2012082931A1 · 2012 [cited by applicant]
WO 2015073633A1 · 2015 [cited by applicant]
WO 2018060522A1 · 2018 [cited by applicant]
WO 2019121846A1 · 2019 [cited by applicant]
WO 2021118900A1 · 2021 [cited by applicant]
Kisselev L., (Structure, 2002, vol. 10: 8-9. [cited by examiner]
Witkowski et al., (Biochemistry 38:11643-11650, 1999. [cited by examiner]
Whisstock et al., (Quarterly Reviews of Biophysics 2003, vol. 36 (3): 307-340. [cited by examiner]
Devos et al., (Proteins: Structure, Function and Genetics, 2000, vol. 41: 98-107. [cited by examiner]
Nardello-Rataj et al., Aqueous solutions of didecyldimethylammonium chloride and octaethylene glycol monododecyl ether: Toward synergistic formulations against enveloped viruses, International Journal of Pharmaceutics, … [cited by applicant]
Aranha, Virological safety of biopharmaceuticals, BioProcess International, 17-20 (2005). [cited by applicant]
Aranha, Current issues in assuring virological safety of biopharmaceuticals, BioProcess International, 10(3):12-17 (2012). [cited by applicant]
Bosley et al., A method of HIV-1 inactivation compatible with antibody-based depletion of abundant proteins from plasma, Proteomics: Clin. Appl., 2(6):904-907 (2008). [cited by applicant]
Conley et al., Evaluation of eco-friendly zwitterionic detergents for enveloped virus inactivation, Biotechnology and Bioengineering, 114(4):813-820 (2017). [cited by applicant]
Durno et al., Viral inactivation: Low pH and detergent, PDA Journal of Phannaceutical Science and Technology, 69(1):163-172 (2015). [cited by applicant]
Edwards et al., Solubilization of lecithin vesicles by C12E8: Structural transitions and temperature effects, Journal of Colloid and Interface Science, 147(1):1-21 (1991). [cited by applicant]
Eshhar et al., Tumor-specific T-bodies: towards clinical application, Cancer Immunol Immunotherapy, 45:131-136 (1997). [cited by applicant]
Hellstern et al., The use of solvent/detergent treatment in pathogen reduction of plasma, Transfusion Medicine and Hemotherapy, 38(1):65-70 (2011). [cited by applicant]
International Application No. PCT/US20/23245, International Preliminary Report on Patentability, mailed Sep. 30, 2021. [cited by applicant]
International Application No. PCT/US20/23245, International Search Report and Written Opinion, mailed Jun. 22, 2020. [cited by applicant]
Kaufman, Large Scale Mammalian Cell Culture, Marcel Dekker, New York, New York, 15-69 (1990). [cited by applicant]
Kragh-Hansen et al., The mechanism of detergent solubilization of liposomes and protein-containing membranes, Biophysical Journal, 75(6):2932-2946 (1998). [cited by applicant]
Laws et al., Estrogenic activity of octylphenol, nonylphenol, bisphenol A and methoxychlor in rats, Toxicological Sciences, 54(1):154-167 (2000). [cited by applicant]
Liumbruno et al., Solvent/detergent plasma: pharmaceutical characteristics and clinical experience, Journal of Thrombosis and Thrombolysis, 39(1):118-128 (2015). [cited by applicant]
Remington, Fundamental strategies for viral clearance part 2: Technical approaches, BioProcess International, 13(5):10-17 (2015). [cited by applicant]
Romanowski et al., Variables affecting titer and long-term stability of virus stocks, BioProcess International, 44-52 (2008). [cited by applicant]
Sambrook et al. Molecular Cloning: A Laboratory Manual, 3rd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (2001). [cited by applicant]
Sambrook et al., Molecular cloning: A laboratory manual, Cold Spring Laboratory Press, Cold Spring Harbor, N.Y. (1989). [cited by applicant]
Viral safety evaluation of biotechnology products derived from cell lines of human or animal origin, Harmonization, I. C. O., Ed., Q5A (1999). [cited by applicant]